RNAi looked doomed to fail — until Alnylam’s science chief found a way

Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

By Michael Gibney • Nov. 13, 2025

Why Pfizer and Novo are duking it out over weight loss startup Metsera

A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena’s high stakes.

By Michael Gibney • Nov. 6, 2025

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

Chinese drugmaker becomes top trial sponsor — and other clinical trends

The industry’s top indication areas for R&D and other shifts in the clinical trial landscape last year.

By Kelly Bilodeau • Nov. 5, 2025

Imunon’s non-viral DNA candidate may have cracked the code in frontline ovarian cancer

Imunon is showing off promising phase 3 data at a gynecologic cancer conference this week.

By Alexandra Pecci • Nov. 5, 2025

Biogen’s yearslong lupus R&D journey could soon pay off

Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.

By Michael Gibney • Nov. 4, 2025

Roche taps an AI specialist to craft new brain drugs

For $55 million, Roche gains access to Manifold Bio’s drug discovery technology, which will be used to develop new “shuttles” that can get medicines across the blood-brain barrier.

By Jacob Bell • Nov. 4, 2025

One of the few late-stage ALS contenders hits a critical juncture

MediciNova has launched a potentially pivotal trial for what it hopes is a disease-modifying ALS drug.

By Meagan Parrish • Oct. 31, 2025

Corporate venture firms stepped in for drug startups during biotech funding pullback

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.

By Gwendolyn Wu • Oct. 31, 2025

Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience

A premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at revolutionary technology that fits into their own expertise.

By Michael Gibney • Oct. 28, 2025

Takeda stakes more than $11B on cancer drugs from China

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be “transformative” for its oncology portfolio.

By Ben Fidler • Oct. 24, 2025

Massachusetts biotech hub is limping amid layoffs and low investment

The state’s difficulties in the last year are indicative of wider industry problems during a time of market trepidation, as optimism gives way to resilience.

By Michael Gibney • Oct. 23, 2025

AI giants Nvidia, Microsoft and Google are making critical moves in pharma R&D

With market caps in the trillions, these tech behemoths are establishing a growing presence in drug development. Here’s what they’re up to.

By Alexandra Pecci • Oct. 22, 2025

In the Salesforce vs. Veeva saga, the clock is ticking for drugmakers

The CRM platform split will be official in 2030, but that still doesn’t leave much time for pharmas and biotechs that have yet to choose which way to go.

By Michael Gibney • Oct. 21, 2025

Ultra-rare diseases got a boost from recent FDA approval signalling more regulatory flexibility

Stealth BioTherapeutics’ FDA win could help build momentum in the broader rare disease space.

By Alexandra Pecci • Oct. 15, 2025

Too much of a good thing? A flood of data is slowing clinical trials.

Pharma companies want to know it all — but cutting out unnecessary data collection could speed drug R&D.

By Kelly Bilodeau • Oct. 15, 2025

What a gene therapy win means for the Huntington’s disease pipeline

Recent results for a Huntington’s gene therapy confer a hopeful sign for R&D in the space.

By Kelly Bilodeau • Oct. 14, 2025

Beyond dire wolves: Could Colossal’s de-extinction work transform human health?

While resurrected animal species grab headlines, Colossal’s behind-the-scenes R&D may be poised to make an impact for humans as well.

By Meagan Parrish • Oct. 10, 2025

Nobel Prize victory spotlights immunology’s value in pharma

While saturated with mature blockbusters, the immunology space is vibrating with new potential breadwinners from the top companies.

By Michael Gibney • Oct. 9, 2025

Vertex’s quest for a breakthrough in Type 1 diabetes

The race is on for an insulin-producing treatment that doesn’t require immune suppressing drugs.

By Kelly Bilodeau • Oct. 8, 2025

As setbacks plague other companies, MindMed becomes a front-runner in the psychedelics race

Challenges faced by other drugmakers have reinforced, rather than discouraged, MindMed’s approach to psychedelic drug R&D for anxiety and other disorders.

By Alexandra Pecci • Oct. 7, 2025

AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others

FluMist Home could be a test case for at-home vaccines against a backdrop of challenging regulatory shifts.

By Alexandra Pecci • Oct. 1, 2025

Top pharma industry conferences in 2026

Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.

By Meagan Parrish • Oct. 1, 2025

Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?

The new treatment may only offer modest benefits, but could gain traction in a market with few other options.

By Kelly Bilodeau • Sept. 30, 2025

As obesity M&A heats up, pharmas could get ‘blinded by opportunity’

With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.

By Kelly Bilodeau • Sept. 29, 2025

Can a multibillion-dollar deal put Pfizer in the obesity big leagues?

After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.

By Michael Gibney • Sept. 25, 2025